Nano-Elastic Vesicles in Oncology: Bridging Formulation Design and Translational Outcomes

Authors

  • Shaik Fazil Fazil Research Scholar, Department of Pharmaceutical Sciences, Shri J.J.T University, Churu Road, Vidyanagari, Churela, Rajasthan 333010
  • Vivek Research Guide, Shri J.J.T University, Churu Road, Vidyanagari, Churela, Rajasthan
  • Ananda Kumar Cettupalli3 Department of pharmaceutical technology, School of Health and medical sciences, Adamas Knowledge city, Adamas University, Barasat-Barrackpore Road, Barbaria, P.O Jagannathpur, District-24 Parganas (North), Kolkata-700 126, West Bengal, India.

Keywords:

Nano-elastic vesicles, transferosomes, ethosomes, anticancer drug delivery, bioavailability, translational nanomedicine.

Abstract

Nano-elastic vesicles (NEVs), including transferosomes, ethosomes, and elastic liposomes, have emerged as promising drug delivery systems to overcome the biopharmaceutical limitations of conventional anticancer therapies. Their unique deformability, nanoscale size, and ability to traverse biological barriers enable improved drug solubility, stability, bioavailability, and site-specific delivery. This review critically examines recent advances in the formulation design, physicochemical characterization, in vitro and in vivo performance, and translational prospects of nano-elastic vesicles in oncology. Emphasis is placed on formulation strategies, mechanisms governing enhanced permeation and retention, pharmacokinetic modulation, therapeutic efficacy, safety considerations, and regulatory challenges. The review aims to bridge the gap between laboratory-scale development and clinical translation, highlighting opportunities and future directions for NEV-based anticancer drug delivery.     

Downloads

Published

2025-10-21

Issue

Vol. 11 No. 4 (2025): Vol 11. No 4 (2025) Volume - 11 Issue - 4

Section

Articles

License

Rights and reuse terms depend on the individual article record. Articles accepted on or after 8 September 2026 are licensed under Creative Commons Attribution 4.0 International (CC BY 4.0), provided appropriate credit is given, a link to the licence is supplied and changes are indicated. Earlier content remains governed by the rights and licence notice applicable to that article and is not retrospectively relicensed by this policy. Third-party material identified under a different notice is excluded from the journal licence.